A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme (STELLAR)
A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme: the STELLAR Study
Sponsor: Amsterdam UMC, location VUmc
This PHASE2/PHASE3 trial investigates GBM and Glioblastoma and is currently ongoing. Amsterdam UMC, location VUmc leads this study, which shows 12 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2/PHASE3
Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
May 2023 — Jul 2024 [monthly]
Unknown Status PHASE2_PHASE3
Status: Recruiting → Unknown Status
-
May 2022 — May 2023 [monthly]
Recruiting PHASE2_PHASE3
-
May 2021 — May 2022 [monthly]
Recruiting PHASE2_PHASE3
▶ Show 7 earlier versions
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Sep 2019 — Nov 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Oct 2018 — Sep 2019 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Oct 2018 [monthly]
Not Yet Recruiting PHASE2_PHASE3
-
Jul 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2_PHASE3
-
Feb 2017 — Jul 2017 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Amsterdam UMC, location VUmc
For direct contact, visit the study record on ClinicalTrials.gov .